Background: End-stage renal disease (ESRD) is a chronic health care problem associated
with multiple co-morbidities and escalating costs. Disregulation of mineral metabolism …

This study was designed to examine the relative safety and efficacy of sevelamer in the
treatment of chronic kidney disease (CKD) patients in comparison to placebo, calcium …

Importance of the field: Altered mineral metabolism in chronic kidney disease (CKD) is
associated with increased morbidity, mortality, hospitalization, cost of care and reduced …

Hyperphosphatemia and dyslipidemia are common clinically significant conditions in end-
stage renal disease (ESRD). Hyperphosphatemia management is essential; however, use of …

Background. It remains unclear which phosphate binders should be preferred for
hyperphosphatemia management in chronic kidney disease (CKD). Methods. We performed …

Aims: This review assesses the evidence for the therapeutic value of sevelamer as a
phosphate binder in adult hemodialysis patients. Evidence review: Strong evidence shows …

Sevelamer (Renagel and Renvela), is an orally administered weakly basic anion exchange
resin that binds dietary phosphate in the gastrointestinal tract, and is approved for use in the …

Background. The relative effectiveness and safety of sevelamer for treatment of
hyperphosphataemia in dialysis patients is uncertain, as compared with calcium-based …

The term 'chronic kidney disease–mineral and bone disorder'(CKD–MBD), coined in 2006,
was introduced in a position statement by the Kidney Disease: Improving Global Outcomes …

As kidney disease progresses, phosphorus retention also increases, and phosphate binders
are used to treat hyperphosphatemia. Clinicians prescribe phosphate binders thinking that …